TY - JOUR AU - Carmeliet, P. AU - Jain, R. K. PY - 2000 DA - 2000// TI - Angiogenesis in cancer and other diseases JO - Nature VL - 407 UR - https://doi.org/10.1038/35025220 DO - 10.1038/35025220 ID - Carmeliet2000 ER - TY - JOUR AU - Chaplain, M. A. J. PY - 1996 DA - 1996// TI - Avascular growth, angiogenesis and vascular growth in solid tumours: The mathematical modelling of the stages of tumour development JO - Math Comput Model VL - 23 UR - https://doi.org/10.1016/0895-7177(96)00019-2 DO - 10.1016/0895-7177(96)00019-2 ID - Chaplain1996 ER - TY - JOUR AU - Billy, F. AU - Ribba, B. AU - Saut, O. AU - Morre-Trouilhet, H. AU - Colin, T. AU - Bresch, D. AU - Boissel, J. -. P. AU - Grenier, E. AU - Flandrois, J. -. P. PY - 2009 DA - 2009// TI - A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy JO - J Theor Biol VL - 260 UR - https://doi.org/10.1016/j.jtbi.2009.06.026 DO - 10.1016/j.jtbi.2009.06.026 ID - Billy2009 ER - TY - JOUR AU - Jain, R. K. PY - 2003 DA - 2003// TI - Molecular regulation of vessel maturation JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm0603-685 DO - 10.1038/nm0603-685 ID - Jain2003 ER - TY - JOUR AU - Mantzaris, N. V. AU - Webb, S. AU - Othmer, H. G. PY - 2004 DA - 2004// TI - Mathematical modeling of tumor-induced angiogenesis JO - J Math Biol VL - 49 UR - https://doi.org/10.1007/s00285-003-0262-2 DO - 10.1007/s00285-003-0262-2 ID - Mantzaris2004 ER - TY - JOUR AU - Friberg, S. AU - Mattson, S. PY - 1997 DA - 1997// TI - On the growth rates of human malignant tumors: implications for medical decision making JO - J Surg Oncol VL - 65 UR - https://doi.org/3.0.CO;2-2 DO - 3.0.CO;2-2 ID - Friberg1997 ER - TY - JOUR AU - Risau, W. PY - 1997 DA - 1997// TI - Mechanisms of angiogenesis JO - Nature VL - 386 UR - https://doi.org/10.1038/386671a0 DO - 10.1038/386671a0 ID - Risau1997 ER - TY - JOUR AU - Reynolds, L. P. AU - Grazul-Bilska, A. T. AU - Redmer, D. A. PY - 2002 DA - 2002// TI - Angiogenesis in the female reproductive organs: pathological implications JO - Int J Exp Pathol VL - 83 UR - https://doi.org/10.1046/j.1365-2613.2002.00277.x DO - 10.1046/j.1365-2613.2002.00277.x ID - Reynolds2002 ER - TY - JOUR AU - Plank, M. J. AU - Sleeman, B. D. PY - 2003 DA - 2003// TI - A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies JO - Math Med Biol VL - 20 UR - https://doi.org/10.1093/imammb/20.2.135 DO - 10.1093/imammb/20.2.135 ID - Plank2003 ER - TY - JOUR AU - Ledzewicz, U. AU - Maurer, H. AU - Schättler, H. PY - 2011 DA - 2011// TI - Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy JO - Math Biosci Eng VL - 8 UR - https://doi.org/10.3934/mbe.2011.8.307 DO - 10.3934/mbe.2011.8.307 ID - Ledzewicz2011 ER - TY - JOUR AU - Folkman, J. PY - 1971 DA - 1971// TI - Tumor angiogenesis: therapeutic implications JO - N Engl J Med VL - 285 UR - https://doi.org/10.1056/NEJM197108122850711 DO - 10.1056/NEJM197108122850711 ID - Folkman1971 ER - TY - JOUR AU - Folkman, J. PY - 1972 DA - 1972// TI - Anti-angiogenesis: new concept for therapy of solid tumors JO - Ann Surg VL - 175 UR - https://doi.org/10.1097/00000658-197203000-00014 DO - 10.1097/00000658-197203000-00014 ID - Folkman1972 ER - TY - JOUR AU - O’Reilly, M. S. AU - Holmgren, L. AU - Chen, C. AU - Folkman, J. PY - 1996 DA - 1996// TI - Angiostatin induces and sustains dormancy of human primary tumors in mice JO - Nat Med VL - 2 UR - https://doi.org/10.1038/nm0696-689 DO - 10.1038/nm0696-689 ID - O’Reilly1996 ER - TY - JOUR AU - Saito, H. AU - Tsujitani, S. AU - Ikeguchi, M. AU - Maeta, M. AU - Kaibara, N. PY - 1998 DA - 1998// TI - Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue JO - Br J Cancer VL - 78 UR - https://doi.org/10.1038/bjc.1998.725 DO - 10.1038/bjc.1998.725 ID - Saito1998 ER - TY - JOUR AU - Gerber, H. -. P. AU - Ferrara, N. PY - 2005 DA - 2005// TI - Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies JO - Cancer Res VL - 65 ID - Gerber2005 ER - TY - JOUR AU - Ferrara, N. AU - Kerbel, R. S. PY - 2005 DA - 2005// TI - Angiogenesis as a therapeutic target JO - Nature VL - 438 UR - https://doi.org/10.1038/nature04483 DO - 10.1038/nature04483 ID - Ferrara2005 ER - TY - JOUR AU - Marrs, J. AU - Zubal, B. A. PY - 2009 DA - 2009// TI - Oncology nursing in a new era: optimizing treatment with bevacizumab JO - Clin J Oncol Nurs VL - 13 UR - https://doi.org/10.1188/09.CJON.564-572 DO - 10.1188/09.CJON.564-572 ID - Marrs2009 ER - TY - JOUR AU - Baumgarten, L. AU - Brucker, D. AU - Tirniceru, A. AU - Kienast, Y. AU - Grau, S. AU - Burgold, S. AU - Herms, J. AU - Winkler, F. PY - 2011 DA - 2011// TI - Bevacizumab has differential and dose-dependent effects on Glioma blood vessels and tumor cells JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-1868 DO - 10.1158/1078-0432.CCR-10-1868 ID - Baumgarten2011 ER - TY - JOUR AU - Samant, R. S. AU - Shevde, L. A. PY - 2011 DA - 2011// TI - Recent advances in anti-angiogenic therapy of cancer JO - Oncotarget VL - 2 UR - https://doi.org/10.18632/oncotarget.234 DO - 10.18632/oncotarget.234 ID - Samant2011 ER - TY - JOUR AU - Lorusso, V. PY - 2008 DA - 2008// TI - Bevacizumab in the treatment of HER2-negative breast cancer JO - Biologics VL - 2 ID - Lorusso2008 ER - TY - CHAP AU - Jain, R. K. AU - Batchelor, T. T. AU - Duda, D. G. AU - Willett, C. G. ED - Teicher, B. A. ED - Ellis, L. M. PY - 2008 DA - 2008// TI - Normalization of Tumor Vasculature and Microenvironment BT - Antiangiogenic agents in cancer therapy PB - Humana Press CY - Totowa UR - https://doi.org/10.1007/978-1-59745-184-0_15 DO - 10.1007/978-1-59745-184-0_15 ID - Jain2008 ER - TY - JOUR AU - Dickson, P. V. AU - Hamner, J. B. AU - Sims, T. L. AU - Fraga, C. H. AU - Ng, C. Y. C. AU - Rajasekeran, S. AU - Hagedorn, N. L. AU - McCarville, M. B. AU - Stewart, C. F. AU - Davidoff, A. M. PY - 2007 DA - 2007// TI - Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0278 DO - 10.1158/1078-0432.CCR-07-0278 ID - Dickson2007 ER - TY - JOUR AU - Jain, R. K. PY - 1987 DA - 1987// TI - Transport of molecules in the tumor interstitium: a review JO - Cancer Res VL - 47 ID - Jain1987 ER - TY - JOUR AU - Jain, R. K. PY - 1988 DA - 1988// TI - Determinants of tumor blood flow: a review JO - Cancer Res VL - 48 ID - Jain1988 ER - TY - JOUR AU - Sato, Y. PY - 2011 DA - 2011// TI - Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy JO - Cancer Sci VL - 102 UR - https://doi.org/10.1111/j.1349-7006.2011.01929.x DO - 10.1111/j.1349-7006.2011.01929.x ID - Sato2011 ER - TY - JOUR AU - D’Onofrio, A. AU - Gandolfi, A. PY - 2009 DA - 2009// TI - A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy JO - Math Med Biol VL - 26 UR - https://doi.org/10.1093/imammb/dqn024 DO - 10.1093/imammb/dqn024 ID - D’Onofrio2009 ER - TY - JOUR AU - Kohandel, M. AU - Kardar, M. AU - Milosevic, M. AU - Sivaloganathan, S. PY - 2007 DA - 2007// TI - Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies JO - Phys Med Biol VL - 52 UR - https://doi.org/10.1088/0031-9155/52/13/001 DO - 10.1088/0031-9155/52/13/001 ID - Kohandel2007 ER - TY - JOUR AU - Stamatakos, G. S. AU - Kolokotroni, E. A. AU - Dionysiou, D. D. AU - Georgiadi, E. C. AU - Desmedt, C. PY - 2010 DA - 2010// TI - An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study JO - J Theor Biol VL - 266 UR - https://doi.org/10.1016/j.jtbi.2010.05.019 DO - 10.1016/j.jtbi.2010.05.019 ID - Stamatakos2010 ER - TY - JOUR AU - Dionysiou, D. D. AU - Stamatakos, G. S. AU - Uzunoglu, N. K. AU - Nikita, K. S. AU - Marioli, A. PY - 2004 DA - 2004// TI - A four-dimensional simulation model of tumour response to radiotherapy in vivo: parametric validation considering radiosensitivity, genetic profile and fractionation JO - J Theor Biol VL - 230 UR - https://doi.org/10.1016/j.jtbi.2004.03.024 DO - 10.1016/j.jtbi.2004.03.024 ID - Dionysiou2004 ER - TY - JOUR AU - Stamatakos, G. S. AU - Dionysiou, D. D. AU - Zacharaki, E. I. AU - Mouravliansky, N. A. AU - Nikita, K. S. AU - Uzunoglu, N. K. PY - 2002 DA - 2002// TI - In silico radiation oncology: combining novel simulation algorithms with current visualization techniques JO - Proc IEEE VL - 90 UR - https://doi.org/10.1109/JPROC.2002.804685 DO - 10.1109/JPROC.2002.804685 ID - Stamatakos2002 ER - TY - JOUR AU - Hahnfeldt, P. AU - Panigrahy, D. AU - Folkman, J. AU - Hlatky, L. PY - 1999 DA - 1999// TI - Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy JO - Cancer Res VL - 59 ID - Hahnfeldt1999 ER - TY - JOUR AU - Sachs, R. K. AU - Hlatky, L. R. AU - Hahnfeldt, P. PY - 2001 DA - 2001// TI - Simple ODE models of tumor growth and anti-angiogenic or radiation treatment JO - Math Comput Model VL - 33 UR - https://doi.org/10.1016/S0895-7177(00)00316-2 DO - 10.1016/S0895-7177(00)00316-2 ID - Sachs2001 ER - TY - JOUR AU - Amster, P. AU - Berezansky, L. AU - Idels, L. PY - 2012 DA - 2012// TI - Periodic solutions of angiogenesis models with time lags JO - Nonlinear Anal Real World Appl VL - 13 UR - https://doi.org/10.1016/j.nonrwa.2011.07.035 DO - 10.1016/j.nonrwa.2011.07.035 ID - Amster2012 ER - TY - JOUR AU - D’ Onofrio, A. AU - Gandolfi, A. PY - 2004 DA - 2004// TI - Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999) JO - Math Biosci VL - 191 UR - https://doi.org/10.1016/j.mbs.2004.06.003 DO - 10.1016/j.mbs.2004.06.003 ID - D’ Onofrio2004 ER - TY - JOUR AU - Benzekry, S. AU - Chapuisat, G. AU - Ciccolini, J. AU - Erlinger, A. AU - Hubert, F. PY - 2012 DA - 2012// TI - A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology JO - CR Math VL - 350 UR - https://doi.org/10.1016/j.crma.2011.11.019 DO - 10.1016/j.crma.2011.11.019 ID - Benzekry2012 ER - TY - JOUR AU - Ledzewicz, U. AU - Schättler, H. PY - 2012 DA - 2012// TI - Multi-input optimal control problems for combined tumor anti-angiogenic and radiotherapy treatments JO - J Optim Theory Appl VL - 153 UR - https://doi.org/10.1007/s10957-011-9954-8 DO - 10.1007/s10957-011-9954-8 ID - Ledzewicz2012 ER - TY - JOUR AU - Ergun, A. AU - Camphausen, K. AU - Wein, L. M. PY - 2003 DA - 2003// TI - Optimal scheduling of radiotherapy and angiogenic inhibitors JO - Bull Math Biol VL - 65 UR - https://doi.org/10.1016/S0092-8240(03)00006-5 DO - 10.1016/S0092-8240(03)00006-5 ID - Ergun2003 ER - TY - STD TI - Swierniak A. Control problems related to three compartmental model of combined anticancer therapy. IEEE. 2012;1428–1433. ID - ref38 ER - TY - JOUR AU - D’ Onofrio, A. AU - Gandolfi, A. PY - 2010 DA - 2010// TI - Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular “pruning" JO - J Theor Biol VL - 264 UR - https://doi.org/10.1016/j.jtbi.2010.01.023 DO - 10.1016/j.jtbi.2010.01.023 ID - D’ Onofrio2010 ER - TY - JOUR AU - Bodnar, M. AU - Foryś, U. PY - 2009 DA - 2009// TI - Influence of time delays on the Hahnfeldt et al. angiogenesis model dynamics JO - Appl Math VL - 36 ID - Bodnar2009 ER - TY - BOOK AU - Swierniak, A. AU - Klamka, J. PY - 2013 DA - 2013// TI - Controllability of a model of treatment response to combined anticancer therapy PB - BIOTECHNO CY - Lisbon ID - Swierniak2013 ER - TY - JOUR AU - Kovács, L. AU - Szeles, A. AU - Sápi, J. AU - Drexler, D. A. AU - Rudas, I. AU - Harmati, I. AU - Sápi, Z. PY - 2014 DA - 2014// TI - Model-based angiogenic inhibition of tumor growth using modern robust control method JO - Comput Methods Prog Biomed VL - 114 UR - https://doi.org/10.1016/j.cmpb.2014.01.002 DO - 10.1016/j.cmpb.2014.01.002 ID - Kovács2014 ER - TY - JOUR AU - Poleszczuk, J. AU - Bodnar, M. AU - Foryś, U. PY - 2011 DA - 2011// TI - New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model JO - Math Biosci Eng VL - 8 UR - https://doi.org/10.3934/mbe.2011.8.591 DO - 10.3934/mbe.2011.8.591 ID - Poleszczuk2011 ER - TY - STD TI - Poleszczuk J, Hahnfeldt P, Enderling H. Therapeutic implications from sensitivity analysis of tumor angiogenesis models. PLoS One. 2015;10. ID - ref44 ER - TY - STD TI - Stamatakos G, Dionysiou D, Lunzer A, Belleman R, Kolokotroni E, Georgiadi E, Erdt M, Pukacki J, Rueping S, Giatili S, d’ Onofrio A, Sfakianakis S, Marias K, Desmedt C, Tsiknakis M, Graf N. The technologically integrated oncosimulator: combining multiscale cancer modeling with information technology in the in silico oncology context. IEEE J Biomedical Health Inform. 2014;18:840–54. ID - ref45 ER - TY - STD TI - Stamatakos GS, Georgiadi EC, Graf N, Kolokotroni EA, Dionysiou DD. Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model. PLoS One. 2011;6. ID - ref46 ER - TY - JOUR AU - Ubezio, P. AU - Cameron, D. PY - 2008 DA - 2008// TI - Cell killing and resistance in pre-operative breast cancer chemotherapy JO - BMC Cancer VL - 8 UR - https://doi.org/10.1186/1471-2407-8-201 DO - 10.1186/1471-2407-8-201 ID - Ubezio2008 ER - TY - BOOK AU - Argyri, K. D. AU - Dionysiou, D. D. AU - Stamatakos, G. S. PY - 2012 DA - 2012// TI - Modeling the interplay between pathological angiogenesis and solid tumor growth: The anti-angiogenic treatment effect PB - IEEE CY - Athens ID - Argyri2012 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Lowengrub, J. S. AU - Frieboes, H. B. AU - Jin, F. AU - Chuang, Y. -. L. AU - Li, X. AU - Macklin, P. AU - Wise, S. M. AU - Cristini, V. PY - 2010 DA - 2010// TI - Nonlinear modelling of cancer: bridging the gap between cells and tumours JO - Nonlinearity VL - 23 UR - https://doi.org/10.1088/0951-7715/23/1/R01 DO - 10.1088/0951-7715/23/1/R01 ID - Lowengrub2010 ER - TY - JOUR AU - Folkman, J. PY - 1990 DA - 1990// TI - What is the evidence that tumors are angiogenesis dependent? JO - J Natl Cancer Inst VL - 82 UR - https://doi.org/10.1093/jnci/82.1.4 DO - 10.1093/jnci/82.1.4 ID - Folkman1990 ER - TY - JOUR AU - Arbiser, J. L. AU - Moses, M. A. AU - Fernandez, C. A. AU - Ghiso, N. AU - Cao, Y. AU - Klauber, N. AU - Frank, D. AU - Brownlee, M. AU - Flynn, E. AU - Parangi, S. AU - Byers, H. R. AU - Folkman, J. PY - 1997 DA - 1997// TI - Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways JO - Proc Natl Acad Sci U S A VL - 94 UR - https://doi.org/10.1073/pnas.94.3.861 DO - 10.1073/pnas.94.3.861 ID - Arbiser1997 ER - TY - JOUR AU - Vasudev, N. S. AU - Reynolds, A. R. PY - 2014 DA - 2014// TI - Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions JO - Angiogenesis VL - 17 UR - https://doi.org/10.1007/s10456-014-9420-y DO - 10.1007/s10456-014-9420-y ID - Vasudev2014 ER - TY - JOUR AU - Ternant, D. AU - Cézé, N. AU - Lecomte, T. AU - Degenne, D. AU - Duveau, A. -. C. AU - Watier, H. AU - Dorval, E. AU - Paintaud, G. PY - 2010 DA - 2010// TI - An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics JO - Ther Drug Monit VL - 32 UR - https://doi.org/10.1097/FTD.0b013e3181ef582a DO - 10.1097/FTD.0b013e3181ef582a ID - Ternant2010 ER - TY - JOUR AU - Lu, J. -. F. AU - Bruno, R. AU - Eppler, S. AU - Novotny, W. AU - Lum, B. AU - Gaudreault, J. PY - 2008 DA - 2008// TI - Clinical pharmacokinetics of bevacizumab in patients with solid tumors JO - Cancer Chemother Pharmacol VL - 62 UR - https://doi.org/10.1007/s00280-007-0664-8 DO - 10.1007/s00280-007-0664-8 ID - Lu2008 ER - TY - JOUR AU - Gaudreault, J. AU - Greig, G. AU - Cosson, V. AU - Gupta, M. AU - Jumbe, N. AU - Hooker, A. C. PY - 2008 DA - 2008// TI - Population pharmacokinetics of bevacizumab JO - ASCO Meeting Abstracts VL - 26 ID - Gaudreault2008 ER - TY - BOOK PY - 2009 DA - 2009// TI - Pharmacology: principles and practice PB - Elsevier/Academic Press CY - Amsterdam ; Boston ID - ref57 ER - TY - BOOK PY - 2013 DA - 2013// TI - Medical physiology: principles for clinical medicine PB - Wilkins CY - Philadelphia ID - ref58 ER - TY - JOUR AU - Rein, D. T. AU - Volkmer, A. K. AU - Volkmer, J. AU - Beyer, I. M. AU - Janni, W. AU - Fleisch, M. C. AU - Welter, A. K. AU - Bauerschlag, D. AU - Schöndorf, T. AU - Breidenbach, M. PY - 2012 DA - 2012// TI - Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer JO - Oncol Lett VL - 3 ID - Rein2012 ER - TY - JOUR AU - Higgins, B. AU - Kolinsky, K. AU - Linn, M. AU - Adames, V. AU - Zhang, Y. -. E. AU - Moisa, C. AU - Dugan, U. AU - Heimbrook, D. AU - Packman, K. PY - 2007 DA - 2007// TI - Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model JO - Anticancer Res VL - 27 ID - Higgins2007 ER - TY - JOUR AU - Hoang, T. AU - Huang, S. AU - Armstrong, E. AU - Eickhoff, J. C. AU - Harari, P. M. PY - 2012 DA - 2012// TI - Enhancement of radiation response with bevacizumab JO - J Exp Clin Cancer Res VL - 31 UR - https://doi.org/10.1186/1756-9966-31-37 DO - 10.1186/1756-9966-31-37 ID - Hoang2012 ER - TY - JOUR AU - Selvakumaran, M. AU - Yao, K. S. AU - Feldman, M. D. AU - O’Dwyer, P. J. PY - 2008 DA - 2008// TI - Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis JO - Biochem Pharmacol VL - 75 UR - https://doi.org/10.1016/j.bcp.2007.09.029 DO - 10.1016/j.bcp.2007.09.029 ID - Selvakumaran2008 ER - TY - JOUR AU - Drevs, J. PY - 2008 DA - 2008// TI - VEGF and angiogenesis: implications for breast cancer therapy JO - Eur J Cancer Suppl VL - 6 UR - https://doi.org/10.1016/S1359-6349(08)70287-8 DO - 10.1016/S1359-6349(08)70287-8 ID - Drevs2008 ER - TY - JOUR AU - Wu, F. AU - Tamhane, M. AU - Morris, M. E. PY - 2012 DA - 2012// TI - Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice JO - AAPS J VL - 14 UR - https://doi.org/10.1208/s12248-012-9342-9 DO - 10.1208/s12248-012-9342-9 ID - Wu2012 ER - TY - JOUR AU - Salaun, P. -. Y. AU - Bodet-Milin, C. AU - Frampas, E. AU - Oudoux, A. AU - Saï-Maurel, C. AU - Faivre-Chauvet, A. AU - Barbet, J. AU - Paris, F. AU - Kraeber-Bodéré, F. PY - 2010 DA - 2010// TI - Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.24792 DO - 10.1002/cncr.24792 ID - Salaun2010 ER - TY - STD TI - European Medicines Agency. Annex I summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Accessed 1 Nov 2015. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf ID - ref66 ER - TY - JOUR AU - Raue, A. AU - Kreutz, C. AU - Theis, F. J. AU - Timmer, J. PY - 2012 DA - 2012// TI - Joining forces of Bayesian and frequentist methodology: a study for inference in the presence of non-identifiability JO - Philos Trans R Soc A Math Phys Eng Sci VL - 371 UR - https://doi.org/10.1098/rsta.2011.0544 DO - 10.1098/rsta.2011.0544 ID - Raue2012 ER - TY - JOUR AU - Kreutz, C. AU - Raue, A. AU - Timmer, J. PY - 2012 DA - 2012// TI - Likelihood based observability analysis and confidence intervals for predictions of dynamic models JO - BMC Syst Biol VL - 6 UR - https://doi.org/10.1186/1752-0509-6-120 DO - 10.1186/1752-0509-6-120 ID - Kreutz2012 ER - TY - JOUR AU - Raue, A. AU - Becker, V. AU - Klingmüller, U. AU - Timmer, J. PY - 2010 DA - 2010// TI - Identifiability and observability analysis for experimental design in nonlinear dynamical models JO - Chaos VL - 20 UR - https://doi.org/10.1063/1.3528102 DO - 10.1063/1.3528102 ID - Raue2010 ER - TY - JOUR AU - Raue, A. AU - Kreutz, C. AU - Maiwald, T. AU - Bachmann, J. AU - Schilling, M. AU - Klingmuller, U. AU - Timmer, J. PY - 2009 DA - 2009// TI - Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood JO - Bioinformatics VL - 25 UR - https://doi.org/10.1093/bioinformatics/btp358 DO - 10.1093/bioinformatics/btp358 ID - Raue2009 ER - TY - JOUR AU - Hanin, L. G. PY - 2002 DA - 2002// TI - Identification problem for stochastic models with application to carcinogenesis, cancer detection and radiation biology JO - Discret Dyn Nat Soc VL - 7 UR - https://doi.org/10.1080/1026022021000001454 DO - 10.1080/1026022021000001454 ID - Hanin2002 ER - TY - BOOK AU - Stamatakos, G. S. PY - 2010 DA - 2010// TI - In silico oncology part i: clinically oriented cancer multilevel modeling based on discrete event simulation PB - CRC Press CY - Boca Raton ID - Stamatakos2010 ER - TY - BOOK AU - Komarova, N. L. PY - 2010 DA - 2010// TI - Building stochastic models for cancer growth and treatment PB - CRC Press CY - Boca Raton ID - Komarova2010 ER - TY - JOUR AU - Perfahl, H. AU - Byrne, H. M. AU - Chen, T. AU - Estrella, V. AU - Alarcón, T. AU - Lapin, A. AU - Gatenby, R. A. AU - Gillies, R. J. AU - Lloyd, M. C. AU - Maini, P. K. AU - Reuss, M. AU - Owen, M. R. PY - 2011 DA - 2011// TI - Multiscale modelling of vascular tumour growth in 3d: the roles of domain size and boundary conditions JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0014790 DO - 10.1371/journal.pone.0014790 ID - Perfahl2011 ER - TY - JOUR AU - Spill, F. AU - Guerrero, P. AU - Alarcon, T. AU - Maini, P. K. AU - Byrne, H. M. PY - 2015 DA - 2015// TI - Mesoscopic and continuum modelling of angiogenesis JO - J Math Biol VL - 70 UR - https://doi.org/10.1007/s00285-014-0771-1 DO - 10.1007/s00285-014-0771-1 ID - Spill2015 ER -